Patents by Inventor Matthew Stuible
Matthew Stuible has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9617337Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: April 25, 2016Date of Patent: April 11, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Patent number: 9493562Abstract: Antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. These antibodies or antigen binding fragments may have the ability of inhibiting differentiation of osteoclasts and/or the ability of inhibiting the bone resorption activity of osteoclasts. Compositions and cells expressing anti-Siglec-15 antibodies or antigen binding fragments are also disclosed herewith. Anti-Siglec-15 antibodies may also be useful for the treatment of bone loss, or bone diseases. Methods for the detection or diagnosis of bone loss or bone-related diseases are also described.Type: GrantFiled: July 17, 2013Date of Patent: November 15, 2016Assignee: Alethia Biotherapeutics Inc.Inventors: Matthew Stuible, Gilles Bernard Tremblay, Traian Sulea, Anna N. Moraitis, Mario Filion
-
Publication number: 20160289325Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: April 25, 2016Publication date: October 6, 2016Inventors: Gilles Bernard TREMBLAY, Mario FILION, Matthew STUIBLE
-
Patent number: 9388242Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: September 4, 2014Date of Patent: July 12, 2016Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Publication number: 20150139982Abstract: Antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. These antibodies or antigen binding fragments may have the ability of inhibiting differentiation of osteoclasts and/or the ability of inhibiting the bone resorption activity of osteoclasts. Compositions and cells expressing anti-Siglec-15 antibodies or antigen binding fragments are also disclosed herewith. Anti-Siglec-15 antibodies may also be useful for the treatment of bone loss, or bone diseases. Methods for the detection or diagnosis of bone loss or bone-related diseases are also described.Type: ApplicationFiled: July 17, 2013Publication date: May 21, 2015Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Matthew Stuible, Gilles Bernard Tremblay, Traian Sulea, Anna N. Moraitis, Mario Filion
-
Publication number: 20150044722Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: September 4, 2014Publication date: February 12, 2015Inventors: Gilles Bernard TREMBLAY, Mario FILION, Matthew STUIBLE
-
Patent number: 8900579Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: January 7, 2014Date of Patent: December 2, 2014Assignee: Alethia Biotherapuetics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Publication number: 20140205603Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: January 7, 2014Publication date: July 24, 2014Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Gilles Bernard TREMBLAY, Mario FILION, Matthew STUIBLE
-
Patent number: 8741289Abstract: Novel antibodies and antigen binding fragments that specifically binds to S?glec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of S?glec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of S?glec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: October 6, 2010Date of Patent: June 3, 2014Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Publication number: 20130039915Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: October 6, 2010Publication date: February 14, 2013Applicant: ALETHIA BIOTHERAPEUTICS INCInventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible